



www.genfit.com

GENFIT: VOTING RESULTS FROM THE COMBINED GENERAL MEETING HELD ON JUNE 28TH, 2011

**Management Board recommendations largely
followed by shareholders**

Lille (France), Cambridge (Massachusetts, United States), July 1st, 2011 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced the results of voting at its combined General Meeting held on June 28th, 2011 in Lille (France).

All the resolutions of the Ordinary General Meeting were approved with a substantial majority. In particular, the annual reports as well as the corporate and consolidated financial statements for the 2010 financial year were endorsed by 92.5% of the votes cast.

All the resolutions proposed to the Extraordinary General Meeting related to the renewal of delegations granted to the Management Board by the Extraordinary General Meeting held on December 1st, 2009 and concerning a capital increase were also approved, except those that aimed to allocate part of the capital increase to employees within the specific context of a savings plan to be set up by the Company.

9,366,463 of a total of 11,622,166 shares were recorded, corresponding to a quorum of 80.31%.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr